Victory Capital Management
SPRY icon

Victory Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Victory Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-199,153
Closed -$2M – 2512
2025
Q3 		$2M Buy
+199,153
New +$2.86M ﹤0.01% 1595
2021
Q3 		– Sell
-28,970
Closed -$895K – 2844
2021
Q2 		$895K Sell
28,970
-1,900
-6% -$60.9K ﹤0.01% 1934
2021
Q1 		$1.35M Sell
30,870
-11,810
-28% -$559K ﹤0.01% 1770
2020
Q4 		$1.98M Buy
+42,680
New +$1.43M ﹤0.01% 1520

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management's SPRY Position: Q4 2025 in Review

Victory Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 199,153 shares — an estimated $2M sold.

Victory Capital Management first reported a position in SPRY in Q4 2020 and held it in 4 quarters. The position peaked at $2M in Q3 2025. 190 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Victory Capital Management reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Victory Capital Management sold 199,153 ARS Pharmaceuticals shares in Q4 2025, an estimated $2M.
  • Victory Capital Management first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Victory Capital Management's ARS Pharmaceuticals position peaked at $2M in Q3 2025.
  • 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Victory Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.